Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Subcutaneous REGEN-COV Antibody Combination in Early SARS-CoV-2 Infection

Meagan P. O’Brien, Eduardo Forleo-Neto, Neena Sarkar, Flonza Isa, Peijie Hou, Kuo-Chen Chan, Bret J. Musser, Katharine J. Bar, Ruanne V. Barnabas, Dan H. Barouch, Myron S. Cohen, Christopher B. Hurt, Dale R. Burwen, Mary A. Marovich, Ingeborg Heirman, John D. Davis, Kenneth C. Turner, Divya Ramesh, Adnan Mahmood, Andrea T. Hooper, Jennifer D. Hamilton, Yunji Kim, Lisa A. Purcell, Alina Baum, Christos A. Kyratsous, James Krainson, Richard Perez-Perez, Rizwana Mohseni, Bari Kowal, A. Thomas DiCioccio, Neil Stahl, Leah Lipsich, Ned Braunstein, Gary Herman, George D. Yancopoulos, David M. Weinreich, for the Covid-19 Phase 3 Prevention Trial Team
doi: https://doi.org/10.1101/2021.06.14.21258569
Meagan P. O’Brien
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: meagan.obrien@regeneron.com
Eduardo Forleo-Neto
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Neena Sarkar
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Flonza Isa
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peijie Hou
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kuo-Chen Chan
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bret J. Musser
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Katharine J. Bar
2Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Department of Microbiology, University of Pennsylvania, Philadelphia, PA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ruanne V. Barnabas
3Department of Global Health, University of Washington, Seattle, WA, USA; Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA, USA; Department of Epidemiology, University of Washington, Seattle, WA, USA; Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dan H. Barouch
4Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Myron S. Cohen
5Institute for Global Health and Infectious Diseases, University of North Carolina, Chapel Hill, NC, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher B. Hurt
5Institute for Global Health and Infectious Diseases, University of North Carolina, Chapel Hill, NC, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dale R. Burwen
6National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mary A. Marovich
6National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ingeborg Heirman
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John D. Davis
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kenneth C. Turner
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Divya Ramesh
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Adnan Mahmood
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrea T. Hooper
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jennifer D. Hamilton
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yunji Kim
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lisa A. Purcell
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alina Baum
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christos A. Kyratsous
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James Krainson
7Clinical Trials of Florida, LLC, Miami, FL, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard Perez-Perez
8Medical Research of Westchester, Miami, FL, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rizwana Mohseni
9Catalina Research Institute, LLC, Montclair, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bari Kowal
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. Thomas DiCioccio
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Neil Stahl
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Leah Lipsich
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ned Braunstein
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gary Herman
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
George D. Yancopoulos
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David M. Weinreich
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Background Casirivimab and imdevimab administered together (REGEN-COV™) markedly reduces the risk of hospitalization or death in high-risk, symptomatic individuals with COVID-19. Here, we report phase 3 results of early treatment of asymptomatic, SARS-CoV-2–positive adults and adolescents with subcutaneous REGEN-COV.

Methods Individuals ≥12 years of age were eligible if identified within 96 hours of a household contact being diagnosed as SARS-CoV-2-positive; 314 were randomized 1:1 to receive subcutaneous REGEN-COV 1200mg or placebo. The primary endpoint was the proportion of infected participants without evidence of prior immunity (i.e., SARS-CoV-2-RT-qPCR–positive/seronegative) who subsequently developed symptomatic Covid-19 during a 28-day efficacy assessment period.

Results Subcutaneous REGEN-COV 1200mg significantly prevented progression from asymptomatic to symptomatic disease compared with placebo (31.5% relative risk reduction; 29/100 [29.0%] vs. 44/104 [42.3%], respectively; P=0.0380). REGEN-COV also reduced the overall population burden of high viral load weeks (39.7% reduction vs. placebo; 48 vs. 82 total weeks; P=0.0010) and of symptomatic weeks (45.3% reduction vs. placebo; 89.6 vs. 170.3 total weeks; P=0.0273), the latter corresponding to an approximately 5.6-day reduction per symptomatic participant. Six placebo-treated participants had a Covid-19-related hospitalization or ER visit versus none for those receiving REGEN-COV. The proportion of participants receiving placebo who had ≥1 treatment-emergent adverse events was 48.1% compared to 33.5% for those receiving REGEN-COV, including Covid-19-related (39.7% vs. 25.8%, respectively) or non-Covid-19-related (16.0% vs. 11.0%, respectively) events.

Conclusions Subcutaneous REGEN-COV 1200mg prevented progression from asymptomatic to symptomatic infection, reduced the duration of high viral load and symptoms, and was well tolerated.

(ClinicalTrials.gov number, NCT04452318.)

Competing Interest Statement

ICMJE disclosure forms provided by the authors are available with the full text of this article.

Clinical Trial

NCT04452318

Funding Statement

Supported by Regeneron Pharmaceuticals, Inc. and F. Hoffmann-La Roche Ltd. This trial was conducted jointly with the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH). The CoVPN is supported by cooperative agreement awards from NIAID NIH. The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The work on this study was supported by CoVPN award number UM1AI068619.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Ethics approval was obtained from the following ethics review boards: WCG IRB, Puyallup, WA (IRB00000533); Lifespan Rhode Island Hospital IRB 2, Providence, RI (IRB# 00004624); Stanford University Research Compliance Office, Palo Alto, CA (IRB# 00004593); Geisinger Institutional Review Board GRIB, Danville, PA (IRB00008345); Advarra IRB, Columbia, MD (IRB00000971).

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Qualified researchers may request access to study documents (including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan) that support the methods and findings reported in this manuscript. Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification. Submit requests to https://vivli.org/.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted June 14, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Subcutaneous REGEN-COV Antibody Combination in Early SARS-CoV-2 Infection
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Subcutaneous REGEN-COV Antibody Combination in Early SARS-CoV-2 Infection
Meagan P. O’Brien, Eduardo Forleo-Neto, Neena Sarkar, Flonza Isa, Peijie Hou, Kuo-Chen Chan, Bret J. Musser, Katharine J. Bar, Ruanne V. Barnabas, Dan H. Barouch, Myron S. Cohen, Christopher B. Hurt, Dale R. Burwen, Mary A. Marovich, Ingeborg Heirman, John D. Davis, Kenneth C. Turner, Divya Ramesh, Adnan Mahmood, Andrea T. Hooper, Jennifer D. Hamilton, Yunji Kim, Lisa A. Purcell, Alina Baum, Christos A. Kyratsous, James Krainson, Richard Perez-Perez, Rizwana Mohseni, Bari Kowal, A. Thomas DiCioccio, Neil Stahl, Leah Lipsich, Ned Braunstein, Gary Herman, George D. Yancopoulos, David M. Weinreich, for the Covid-19 Phase 3 Prevention Trial Team
medRxiv 2021.06.14.21258569; doi: https://doi.org/10.1101/2021.06.14.21258569
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Subcutaneous REGEN-COV Antibody Combination in Early SARS-CoV-2 Infection
Meagan P. O’Brien, Eduardo Forleo-Neto, Neena Sarkar, Flonza Isa, Peijie Hou, Kuo-Chen Chan, Bret J. Musser, Katharine J. Bar, Ruanne V. Barnabas, Dan H. Barouch, Myron S. Cohen, Christopher B. Hurt, Dale R. Burwen, Mary A. Marovich, Ingeborg Heirman, John D. Davis, Kenneth C. Turner, Divya Ramesh, Adnan Mahmood, Andrea T. Hooper, Jennifer D. Hamilton, Yunji Kim, Lisa A. Purcell, Alina Baum, Christos A. Kyratsous, James Krainson, Richard Perez-Perez, Rizwana Mohseni, Bari Kowal, A. Thomas DiCioccio, Neil Stahl, Leah Lipsich, Ned Braunstein, Gary Herman, George D. Yancopoulos, David M. Weinreich, for the Covid-19 Phase 3 Prevention Trial Team
medRxiv 2021.06.14.21258569; doi: https://doi.org/10.1101/2021.06.14.21258569

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (182)
  • Allergy and Immunology (438)
  • Anesthesia (100)
  • Cardiovascular Medicine (960)
  • Dentistry and Oral Medicine (179)
  • Dermatology (112)
  • Emergency Medicine (261)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (426)
  • Epidemiology (9082)
  • Forensic Medicine (5)
  • Gastroenterology (427)
  • Genetic and Genomic Medicine (1991)
  • Geriatric Medicine (195)
  • Health Economics (409)
  • Health Informatics (1345)
  • Health Policy (665)
  • Health Systems and Quality Improvement (532)
  • Hematology (214)
  • HIV/AIDS (428)
  • Infectious Diseases (except HIV/AIDS) (10911)
  • Intensive Care and Critical Care Medicine (578)
  • Medical Education (202)
  • Medical Ethics (55)
  • Nephrology (225)
  • Neurology (1868)
  • Nursing (110)
  • Nutrition (276)
  • Obstetrics and Gynecology (365)
  • Occupational and Environmental Health (474)
  • Oncology (1014)
  • Ophthalmology (308)
  • Orthopedics (111)
  • Otolaryngology (186)
  • Pain Medicine (128)
  • Palliative Medicine (45)
  • Pathology (268)
  • Pediatrics (591)
  • Pharmacology and Therapeutics (279)
  • Primary Care Research (237)
  • Psychiatry and Clinical Psychology (1928)
  • Public and Global Health (4175)
  • Radiology and Imaging (687)
  • Rehabilitation Medicine and Physical Therapy (375)
  • Respiratory Medicine (555)
  • Rheumatology (229)
  • Sexual and Reproductive Health (191)
  • Sports Medicine (178)
  • Surgery (210)
  • Toxicology (39)
  • Transplantation (111)
  • Urology (82)